Your session is about to expire
← Back to Search
Erenumab-aooe for Trigeminal Neuropathy
Study Summary
This trial is testing whether a new drug, erenumab-aooe, is effective in reducing pain for people with trigeminal neuropathic pain, compared to placebo. The trial will involve 40 people total, who will be randomly assigned to either receive the drug or placebo. There will be 6 clinic visits over 21 weeks, during which changes in pain intensity and other pain-related outcomes will be assessed.
- Trigeminal Neuropathy
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What potential risks should people be aware of when using Erenumab-aooe?
"As Erenumab-aooe is currently undergoing Phase 2 trials, the safety rating of this medication has been assessed as a score of 2. This reflects that while clinical data on its efficacy is yet to be collected, there are some studies which demonstrate it's security."
Is this clinical trial a pioneering effort?
"Presently, Erenumab-aooe is the focus of 18 clinical trials distributed across 179 cities and 32 countries. The inaugural trial for this drug was commissioned by Amgen in 2019 and saw 456 participants complete its Phase 3 approval stage. Since then, a total of 18338 investigations have been initiated concerning this medication."
What is the upper limit for participants in this medical trial?
"Affirmative. The clinical trial data stored on clinicaltrials.gov affirms that the study, which was launched April 1st 2022, is currently recruiting participants. A total of 40 individuals are necessary to be recruited from one medical centre."
Is the age limit for this research endeavor restricted to those over thirty years of age?
"Patients eligible for this trial must be between 18 and 65 years old. For those below the age of consent, there are 10 studies available, while 155 experiments have been designed with seniors in mind."
Has Erenumab-aooe been tested in any prospective investigations?
"Presently, 18 clinical studies related to Erenumab-aooe are in progress. Three of these trials have advanced to Phase 3 status. Rochester, Minnesota is the epicentre for much of this research; however, 549 sites globally offer access to treatment with this medication."
Is enrollment in this experiment open to participants at the moment?
"According to clinicaltrials.gov, this ongoing recruiting process was initiated on April 1st 2022 and has been recently updated as of May 4th 2022."
Is it possible for me to join this research effort?
"For entry into this clinical trial, subjects must be diagnosed with trigeminal neuropathy and range between 18 to 65 years of age. A total of 40 people will eventually be accepted."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Average response time
- < 2 Days
Most responsive sites:
- University of Maryland, School of Dentistry, Brotman Facial Pain Clinic: < 48 hours
Typically responds via
Share this study with friends
Copy Link
Messenger